Walleye Capital
INMB icon

Walleye Capital’s INmune Bio INMB Stock Holding History

Walleye Capital’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-33,719
Closed -$157K – 4646
2024
Q4 		$157K Buy
+33,719
New +$176K ﹤0.01% 3903
2022
Q1 		– Sell
-17,127
Closed -$175K – 2424
2021
Q4 		$175K Buy
+17,127
New +$254K 0.01% 1517

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PP
Praetorian PR Rincon, Puerto Rico $275M AUM 84.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Walleye Capital's INMB Position: Q1 2025 in Review

Walleye Capital sold out of INmune Bio (INMB) in Q1 2025, closing a stake of 33,719 shares — an estimated $157K sold.

Walleye Capital first reported a position in INMB in Q4 2021 and held it in 2 quarters. The position peaked at $175K in Q4 2021. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2025.

  • Walleye Capital reported no remaining INmune Bio position as of Q1 2025 after selling out during the quarter.
  • Walleye Capital sold 33,719 INmune Bio shares in Q1 2025, an estimated $157K.
  • Walleye Capital first reported a position in INmune Bio in Q4 2021 and held it in 2 quarters.
  • Walleye Capital's INmune Bio position peaked at $175K in Q4 2021.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.